FutureChem Co.Ltd (KQ:220100) — Market Cap & Net Worth
Market Cap & Net Worth: FutureChem Co.Ltd (220100)
FutureChem Co.Ltd (KQ:220100) has a market capitalization of $93.15 Million (₩137.45 Billion) as of September 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #19546 globally and #999 in its home market, demonstrating a -21.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying FutureChem Co.Ltd's stock price ₩6130.00 by its total outstanding shares 22422193 (22.42 Million). Also see 220100 current and non-current assets for a full breakdown of the balance sheet.
FutureChem Co.Ltd Market Cap History: 2016 to 2026
FutureChem Co.Ltd's market capitalization history from 2016 to 2026. Data shows change from $76.53 Million to $93.15 Million (-9.93% CAGR). Also see FutureChem Co.Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
FutureChem Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$235.78 Billion | 0.04% | #413 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$235.78 Billion | 0.04% | #413 of 1384 |
Weight: FutureChem Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
FutureChem Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how FutureChem Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check FutureChem Co.Ltd (220100) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.03x
FutureChem Co.Ltd's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $76.53 Million | $1.63 Billion | -$27.29 Billion | 0.05x | N/A |
| 2017 | $149.32 Million | $3.00 Billion | -$4.49 Billion | 0.05x | N/A |
| 2018 | $101.03 Million | $5.64 Billion | -$11.97 Billion | 0.02x | N/A |
| 2019 | $112.39 Million | $8.17 Billion | -$5.37 Billion | 0.01x | N/A |
| 2020 | $271.88 Million | $11.01 Billion | -$23.10 Billion | 0.02x | N/A |
| 2021 | $203.49 Million | $11.82 Billion | -$3.42 Billion | 0.02x | N/A |
| 2022 | $146.03 Million | $12.57 Billion | -$13.96 Billion | 0.01x | N/A |
| 2023 | $160.31 Million | $13.97 Billion | -$6.71 Billion | 0.01x | N/A |
| 2024 | $263.03 Million | $17.29 Billion | -$9.42 Billion | 0.02x | N/A |
| 2025 | $468.77 Million | $18.67 Billion | -$11.25 Billion | 0.03x | N/A |
Competitor Companies of 220100 by Market Capitalization
Companies near FutureChem Co.Ltd in the global market cap rankings as of September 19, 2026. Review 220100 tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to FutureChem Co.Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
FutureChem Co.Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, FutureChem Co.Ltd's market cap moved from $76.53 Million to $ 93.15 Million, with a yearly change of -9.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩93.15 Million | -80.13% |
| 2025 | ₩468.77 Million | +78.22% |
| 2024 | ₩263.03 Million | +64.08% |
| 2023 | ₩160.31 Million | +9.78% |
| 2022 | ₩146.03 Million | -28.24% |
| 2021 | ₩203.49 Million | -25.15% |
| 2020 | ₩271.88 Million | +141.89% |
| 2019 | ₩112.39 Million | +11.24% |
| 2018 | ₩101.03 Million | -32.34% |
| 2017 | ₩149.32 Million | +95.12% |
| 2016 | ₩76.53 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of FutureChem Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $93.15 Million USD |
| MoneyControl | $93.15 Million USD |
| MarketWatch | $93.15 Million USD |
| marketcap.company | $93.15 Million USD |
| Reuters | $93.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About FutureChem Co.Ltd
FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products i… Read more